Chronic wounds such as diabetic foot ulcers are a huge and growing healthcare burden, often slow to heal and costly to treat. AOTI (LSE:AOTI) has developed a home-based oxygen therapy that its studies suggest heals many such wounds effectively. The question is how it could turn a clinically promising technology into far wider adoption, particularly across the large United States market.

A wound-care technology leader

AOTI, listed on London’s AIM, develops and sells topical wound oxygen therapy, marketed as TWO2, an intermittent oxygen treatment delivered to patients at home for chronic wounds such as diabetic foot ulcers. By applying oxygen directly to the wound in cycles, the therapy aims to accelerate healing where conventional care struggles. AOTI describes itself as the clear leader in topical oxygen therapy, with a large share of that segment, positioning it in a specialised, clinically driven part of the wound-care market.

The recent results

For the six months to 30 June 2026, AOTI reported Revenue of about US$35 million, up around 10%, or about 18% excluding the impact of a change in Arizona Medicaid coverage. Around 57% of revenue came from the US Veterans Administration, growing about 15%, with Medicaid contributing roughly 41%. Cash stood at about US$13.8 million with net Debt of around US$6.3 million. The company holds a dominant position, with about a 75% share of the topical oxygen therapy segment, underlining its market leadership.

The clinical case for adoption

Wider adoption rests on clinical evidence, and AOTI has been building it. It has reported strong real-world healing outcomes, including studies showing a high proportion of hard-to-treat wounds achieving complete healing, and emphasised durable results compared with continuous oxygen and advanced wound-care alternatives. Compelling evidence that its therapy heals wounds that resist other treatments, and does so at home, is central to persuading clinicians, health systems and payers to adopt it more widely, given the high cost and burden of chronic wounds.

The reimbursement opportunity

In the United States, reimbursement is often the key to adoption. AOTI highlighted a proposed Local Coverage Determination from the Centers for Medicare & Medicaid Services affirming coverage for treating diabetic foot ulcers, which, following a comment period, could be finalised within around a year. Management characterised this as potentially transformational. Broad, clear reimbursement from major payers such as Medicare would remove a significant barrier, potentially opening a much larger market and driving substantial growth in adoption of the therapy.

The risks to weigh

Risks apply. AOTI depends heavily on US reimbursement, so changes such as the Arizona Medicaid cessation can hit revenue, and the proposed Medicare coverage is not yet finalised. Reliance on the Veterans Administration and Medicaid concentrates its revenue base. Expanding adoption requires investment, and competition and clinical scrutiny exist in wound care. Carrying net debt requires management, and healthcare policy can change. Converting clinical promise into broad, reimbursed adoption is not guaranteed and depends partly on decisions outside AOTI’s control.

So how could adoption widen?

AOTI could widen adoption by building compelling clinical evidence, securing broad reimbursement – above all the proposed Medicare coverage for diabetic foot ulcers – and expanding beyond its current payers, turning a leading therapy into a mainstream treatment. The recent results, with growing revenue and market leadership, show momentum. Reimbursement, concentration and policy risks are real, and the coverage decision is pending. But with strong outcomes and a potentially transformational coverage change ahead, AOTI has a credible path to far wider use. Investors should watch the Medicare coverage decision, revenue growth and adoption beyond its current payers as the clearest guides to AOTI's trajectory, since broad reimbursement could prove transformational.